FTFilip Trajhan

Filip Trajhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Filip Trajhan has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Adam Pecina

    Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

    1 shared publication
  • Alexandra Dvořáková

    Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

    1 shared publication
  • Charles S. Craik

    University of California, San Francisco

    1 shared publication
  • Eva Tloušt’ová

    Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, Prague 6 16610, Czech Republic

    1 shared publication
  • Hiten D. Madhani

    Department of Biochemistry & Biophysics, University of California San Francisco, UCSF Genentech Hall, 600 16th St Rm N374, San Francisco, California 94158, United States

    1 shared publication
  • Jan Konvalinka

    Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

    1 shared publication

Latest Publications

  • Open Access

    On-Resin Assembly of Macrocyclic Inhibitors of Cryptococcus neoformans May1: A Pathway to Potent Antifungal Agents

    by Robin Kryštůfek, Václav Verner, Pavel Šácha, Martin Hadzima, Filip Trajhan, Jana Starková, Eva Tloušt’ová, Alexandra Dvořáková, Adam Pecina, Jiří Brynda, et al.

    Macrocyclic inhibitors have emerged as a privileged scaffold in medicinal chemistry, offering enhanced selectivity, stability, and pharmacokinetic profiles compared to their linear counterparts. Here, we describe a novel, on-resin macrocyclization strategy for the synthesis of potent inhibitors targeting the secreted protease Major Aspartyl Peptidase 1 in Cryptococcus neoformans, a pathogen responsible for life-threatening fungal infections. By employing diverse aliphatic linkers and statine-based transition-state mimics, we constructed a focused library of 624 macrocyclic compounds. Screening identified several subnanomolar inhibitors with desirable pharmacokinetic and antifungal properties. Lead compound 25 exhibited a Ki of 180 pM, significant selectivity against host proteases, and potent antifungal activity in culture. The streamlined synthetic approach not only yielded drug-like macrocycles with potential in antifungal therapy but also provided insights into structure-activity relationships that can inform broader applications of macrocyclization in drug discovery.